New approach methodologies for metabolic disruption: a high-throughput human liver cell phospholipidosis assay
Archives of Toxicology · 2026-03 · 100 (3) · 1023-1032
DOI: 10.1007/s00204-025-04254-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Toxicology, online erschienen am 10.12.2025. Verfasst von Neele Wewer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dept. Chemical and Product Safety, German Federal Institute for Risk Assessment, Max-Dohrn-Str. 8-10, 10589, Berlin, Germany. Hauptthemen laut MEDLINE: High-Throughput Screening Assays, Phospholipids, Lipidoses, Hepatocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesinstitut für Risikobewertung (BfR).
Abstract (Originalsprache)
Phospholipidosis (PLD) is the excessive accumulation of phospholipids within cells, which is, for example, observed in the liver following exposure to certain chemicals or drugs. Although the precise molecular mechanisms underlying PLD remain incompletely elucidated, it is documented that PLD is frequently induced by cationic amphiphilic compounds. To facilitate the identification of potential PLD inducers across diverse groups of chemicals, the development of novel high-throughput screening methodologies is imperative. Here, an in vitro human liver cell culture system was established for PLD screening, employing the fluorescence-based LipidTox assay in differentiated HepaRG cells in a 96-well format. Cells were treated with a selection of 35 compounds characterized as either PLD inducers or non-inducers, based on previously published in vivo data. Concentration-response curves of phospholipid accumulation were assessed and the results were compared with existing in vivo, in vitro and in silico datasets. The findings confirm the applicability of the LipidTOX assay in differentiated HepaRG cells as a reliable in vitro -based high-throughput screening method for PLD prediction, achieving an overall predictivity of 86%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dept. Chemical and Product Safety, German Federal Institute for Risk Assessment, Max-Dohrn-Str. 8-10, 10589, Berlin, Germany.
- Dept. Chemical and Product Safety, German Federal Institute for Risk Assessment, Max-Dohrn-Str. 8-10, 10589, Berlin, Germany. dajana.lichtenstein@bfr.bund.de.
ORCID-Profile: Neele Wewer, Albert Braeuning, Dajana Lichtenstein
Förderung
- Bundesinstitut für Risikobewertung (BfR)
Zitieren
APA
Wewer, N., Braeuning, A., & Lichtenstein, D. (2026). New approach methodologies for metabolic disruption: a high-throughput human liver cell phospholipidosis assay. Archives of Toxicology, 100(3), 1023-1032. https://doi.org/10.1007/s00204-025-04254-2
Vancouver
Wewer N, Braeuning A, Lichtenstein D. New approach methodologies for metabolic disruption: a high-throughput human liver cell phospholipidosis assay. Archives of Toxicology. 2026;100(3):1023-1032. doi:10.1007/s00204-025-04254-2
BibTeX
@article{Wewer2026,
author = {Wewer, Neele and Braeuning, Albert and Lichtenstein, Dajana},
title = {New approach methodologies for metabolic disruption: a high-throughput human liver cell phospholipidosis assay},
journal = {Archives of Toxicology},
year = {2026},
volume = {100},
number = {3},
pages = {1023--1032},
doi = {10.1007/s00204-025-04254-2}
}
EUVIMED